Taconic Biosciences Secures Exclusive CRISPR Licensing Deal with Helmholtz Munich

Taconic Biosciences Secures Exclusive CRISPR Licensing Deal with Helmholtz Munich

Taconic Biosciences has entered an exclusive license agreement with Helmholtz Munich, a top biomedical research center in Germany, to enhance preclinical research capabilities.

Through this partnership, Taconic gains exclusive rights to a patented CRISPR-based gene editing technology developed at Helmholtz Munich—advancing the creation of genetically modified animal models for biomedical research.

Learn more

Powered By GrowthZone